Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Lock

Showing results (191-200 of 220) with videos related to

Pageof 22
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2019
OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALLKathryn Evans, JianXin Duan, Tara Pritchard, et al.
Leukemia|January 4, 2020
OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesisLioubov Korotchkina, Denis Kazyulkin, Pavel G Komarov, et al.
Pharmacology & Therapeutics|November 7, 2024
Lessons learned from 20 years of preclinical testing in pediatric cancersMalcolm A Smith, Peter J Houghton, Richard B Lock, et al.
Leukemia|December 19, 2019
Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemiaKlaartje Somers, Kathryn Evans, Leanna Cheung, et al.
The Journal of Experimental Medicine|June 27, 2012
Janus-like opposing roles of CD47 in autoimmune brain inflammation in humans and miceMay H Han, Deborah H Lundgren, Siddhartha Jaiswal, et al.
Blood Cancer Journal|November 6, 2024
The third generation AKR1C3-activated prodrug, ACHM-025, eradicates disease in preclinical models of aggressive T-cell acute lymphoblastic leukemiaCara E Toscan, Hannah McCalmont, Amir Ashoorzadeh, et al.
Frontiers in Oncology|June 9, 2022
The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia ProgressionLin Xiao, Mawar Karsa, Emma Ronca, et al.
Cancer Cytopathology|May 27, 2021
The important role of routine cytopathology in pediatric precision oncologyJinhan Xie, Amit Kumar, M Emmy M Dolman, et al.
Cell Reports|November 26, 2013
Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitorsMichaela Waibel, Vanessa S Solomon, Deborah A Knight, et al.
Leukemia|November 15, 2022
Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategyLaurence C Cheung, Carlos Aya-Bonilla, Mark N Cruickshank, et al.
Pageof 22

Showing results (191-200 of 220) with videos related to

Sort By:
Pageof 22
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2019
OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALLKathryn Evans, JianXin Duan, Tara Pritchard, et al.
Leukemia|January 4, 2020
OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesisLioubov Korotchkina, Denis Kazyulkin, Pavel G Komarov, et al.
Pharmacology & Therapeutics|November 7, 2024
Lessons learned from 20 years of preclinical testing in pediatric cancersMalcolm A Smith, Peter J Houghton, Richard B Lock, et al.
Leukemia|December 19, 2019
Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemiaKlaartje Somers, Kathryn Evans, Leanna Cheung, et al.
The Journal of Experimental Medicine|June 27, 2012
Janus-like opposing roles of CD47 in autoimmune brain inflammation in humans and miceMay H Han, Deborah H Lundgren, Siddhartha Jaiswal, et al.
Blood Cancer Journal|November 6, 2024
The third generation AKR1C3-activated prodrug, ACHM-025, eradicates disease in preclinical models of aggressive T-cell acute lymphoblastic leukemiaCara E Toscan, Hannah McCalmont, Amir Ashoorzadeh, et al.
Frontiers in Oncology|June 9, 2022
The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia ProgressionLin Xiao, Mawar Karsa, Emma Ronca, et al.
Cancer Cytopathology|May 27, 2021
The important role of routine cytopathology in pediatric precision oncologyJinhan Xie, Amit Kumar, M Emmy M Dolman, et al.
Cell Reports|November 26, 2013
Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitorsMichaela Waibel, Vanessa S Solomon, Deborah A Knight, et al.
Leukemia|November 15, 2022
Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategyLaurence C Cheung, Carlos Aya-Bonilla, Mark N Cruickshank, et al.
Pageof 22